StocksK › KBH

KB Home (KBH) — Earnings Call X-Ray

Our AI read all 38 of KBH's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q2 2025 · sign up to see
Previous Call Grade
C
Q1 2025
Expected Move
🔒
next 45 days · members
Calls Analyzed
38
2016–2025
Avg Candor
7.4/9
evasion 2.1/9
Guidance LoweredHigh CandorSkeptic ReassuredCritic AmmunitionUnderused Fixed CostsPricing Under PressureMargins ContractingDemand Slowing

Call-by-call analysis

🔒 Q2 2025 earnings call 2025-06-23 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q2 2025 call grade is ready
The full 37-point AI read of KBH's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

C Q1 2025 earnings call 2025-03-24 move ±12.2%

Management lowered guidance against slowing demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: loweredDemand: slowingMargins: contractingBacklog: shrinkingPricing: under pressureCapex: increasing 10 analysts · 17 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsDirection beats results
Candor 8/9
Specificity 8/9
Evasion 2/9
Confidence 6/9
Uncertainty 5/9
Promotion 3/9
Stress 4/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C+ Q4 2024 earnings call 2025-01-13 move ±11.3%

Management lowered guidance against mixed demand signals. The delivery was unusually candid, rich in specifics.

Guidance: loweredDemand: mixedMargins: stableBacklog: shrinkingPricing: under pressureCapex: increasing 6 analysts · 11 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts
Candor 8/9
Specificity 9/9
Evasion 2/9
Confidence 7/9
Uncertainty 5/9
Promotion 3/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

A Q2 2024 earnings call 2024-06-18 move ±9.9%

Management raised guidance against steady demand. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: stableMargins: stableBacklog: stablePricing: raisingCapex: increasing 7 analysts · 14 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
Candor 8/9
Specificity 9/9
Evasion 1/9
Confidence 8/9
Uncertainty 3/9
Promotion 4/9
Stress 2/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B+ Q1 2024 earnings call 2024-03-20 move ±8.8%

Management held guidance steady against accelerating demand. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: acceleratingMargins: stableBacklog: growingPricing: raisingHeadcount: growingCapex: increasing 8 analysts · 16 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts
Candor 7/9
Specificity 8/9
Evasion 1/9
Confidence 8/9
Uncertainty 3/9
Promotion 4/9
Stress 1/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B Q4 2023 earnings call 2024-01-10 move ±9.4%

Management lowered guidance against accelerating demand. The delivery was unusually candid, rich in specifics.

Guidance: loweredDemand: acceleratingMargins: stableBacklog: shrinkingPricing: raisingHeadcount: growingCapex: increasing 10 analysts · 18 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsDirection beats results
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q3 2023 earnings call 2023-09-20 move ±11.5%

Management raised guidance against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: stableMargins: contractingBacklog: shrinkingPricing: raisingCapex: increasing 9 analysts · 15 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsDirection beats results
Candor 8/9
Specificity 9/9
Evasion 2/9
Confidence 7/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

A Q2 2023 earnings call 2023-06-21 move ±8.3%

Management raised guidance against accelerating demand and contracting margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: contractingBacklog: growingPricing: raisingCapex: increasing 9 analysts · 19 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Prepayments growing✓ Volume step-up ahead
Candor 8/9
Specificity 8/9
Evasion 1/9
Confidence 8/9
Uncertainty 4/9
Promotion 5/9
Stress 1/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
YES Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q1 2023 2023-03-22 B+ raisedacceleratingcontracting 7/9 2/9
Q4 2022 2023-01-11 D loweredslowingcontracting 8/9 3/9
Q3 2022 2022-09-21 D loweredslowingcontracting 7/9 4/9
Q2 2022 2022-06-22 C+ maintainedslowingexpanding 7/9 2/9
Q1 2022 2022-03-23 B maintainedacceleratingexpanding 7/9 2/9
Q4 2021 2022-01-12 A raisedstableexpanding 8/9 1/9
Q3 2021 2021-09-22 B+ raisedstableexpanding 8/9 2/9
Q2 2021 2021-06-23 A raisedacceleratingexpanding 8/9 1/9
Q1 2021 2021-03-24 B+ raisedstableexpanding 7/9 2/9
Q4 2020 2021-01-13 A raisedacceleratingexpanding 8/9 1/9
Q3 2020 2020-09-22 B+ raisedacceleratingexpanding 7/9 1/9
Q2 2020 2020-06-24 C+ maintainedacceleratingexpanding 7/9 2/9
Q1 2020 2020-03-26 C withdrawnslowingexpanding 7/9 2/9
Q4 2019 2020-01-09 B+ maintainedacceleratingexpanding 7/9 2/9
Q3 2019 2019-09-25 A raisedacceleratingexpanding 7/9 3/9
Q2 2019 2019-06-26 B+ maintainedacceleratingexpanding 7/9 4/9
Q1 2019 2019-03-26 C+ maintainedacceleratingexpanding 7/9 3/9
Q4 2018 2019-01-09 D withdrawnslowingstable 7/9 3/9
Q3 2018 2018-09-26 C+ loweredstableexpanding 8/9 1/9
Q2 2018 2018-06-28 B+ raisedacceleratingexpanding 7/9 2/9
Q1 2018 2018-03-22 B+ raisedacceleratingexpanding 7/9 2/9
Q4 2017 2018-01-10 A raisedacceleratingexpanding 7/9 3/9
Q3 2017 2017-09-29 B raisedstableexpanding 7/9 4/9
Q2 2017 2017-06-27 A raisedacceleratingexpanding 7/9 2/9
Q1 2017 2017-03-23 A raisedacceleratingexpanding 8/9 1/9
Q4 2016 2017-01-11 B+ maintainedacceleratingcontracting 8/9 2/9
Q3 2016 2016-09-21 C loweredacceleratingexpanding 8/9 3/9
Q2 2016 2016-06-21 B+ raisedacceleratingexpanding 7/9 2/9
Q1 2016 2016-03-23 C+ maintainedstableexpanding 7/9 3/9
Q4 2015 2016-01-07 C loweredmixedcontracting 8/9 2/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of KBH's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

C+ Q2 2022 earnings call 2022-06-22

1 more research questions answered NO

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAP · Advance Auto Parts, Inc.ABCAF · Athabasca Minerals, Inc.ABDC · Alcentra Capital'sABMD · Abiomed, Inc.ABNRY · ABN AMRO Bank N.V.ABOS · Acumen Pharmaceuticals,

KBDC   All “K” companies    KBNT

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.